Header Logo

Connection

Mary Fidler to Antineoplastic Agents

This is a "connection" page, showing publications Mary Fidler has written about Antineoplastic Agents.
Connection Strength

0.265
  1. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.169
  2. Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
    View in: PubMed
    Score: 0.096
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.